Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) filed a Form 8-K on May 14, 2026, to announce its financial results for the quarter ended March 31, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K serves as a notification that a press release containing these details (Exhibit 99.1) has been issued, but the specific financial data is not embedded in the text of this report.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The filing references an external press release for the comparative analysis of financial results.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished in Item 2.02 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q1 2026 financial figures.
- Verify the company's cash runway and burn rate, as these are not disclosed in the 8-K text.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
- Check for any forward-looking statements or revised guidance in the referenced exhibit.